Raloxifene is a selective modulator of estrogen receptors (agonist/antagonist properties). Raloxifene is indicated for the prevention and treatment of osteoporosis in postmenopausal women.

For postmenopausal osteoporosis prevention, raloxifene is an alternative to conventional hormone replacement therapy (estrogen/progestin); it likely to be more expensive.

Absolute bioavailability of raloxifene is 2%. Raloxifene undergoes extensive first-pass metabolism. The elimination half-life is 27.7 hours.

Active or past history of venous thromboembolic events; lactating women; pregnancy; hypersensitivity to raloxifene

X [FDA]

Infant risk has been demostrataed.

hot flashes (25-30%), leg cramps; it increases the risk of venous thrombosis and is a teratogen.

Adults: prevention and treatment of osteoporosis in postmenopausal women: 60mg PO QD